FDA Drug Recalls

515 recalls, newest first

Apr 28, 2023 Class II · Moderate risk

oxyTOCIN 40 units added to 0.9% sodium chloride 1

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8069-1 D-0740-2023

Apr 28, 2023 Class II · Moderate risk

heparin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-8000-1 D-0739-2023

Apr 28, 2023 Class II · Moderate risk

diphenhydrAMINE 50 mg added to 0.9% sodium chloride 50 mL in 100 mL Partial Additive Bag

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7090-1 D-0738-2023

Apr 28, 2023 Class II · Moderate risk

diphenhydrAMINE 25 mg added to 0.9% sodium chloride 50 mL in 100 mL Partial Additive Bag

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7089-1 D-0737-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7060-1 D-0736-2023

Apr 28, 2023 Class II · Moderate risk

phenylephrine 50 mg added to 0.9% sodium chloride 250 mL*

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7039-1 D-0735-2023

Apr 28, 2023 Class II · Moderate risk

NORepinephrine added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7036-1 D-0734-2023

Apr 28, 2023 Class II · Moderate risk

PHENYLephrine added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7025-1 D-0733-2023

Apr 28, 2023 Class II · Moderate risk

heparin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7023-1 D-0732-2023

Apr 28, 2023 Class II · Moderate risk

heparin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7022-1 D-0731-2023

Apr 28, 2023 Class II · Moderate risk

EPINEPHrine added to dextrose 5%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7019-1 D-0730-2023

Apr 28, 2023 Class II · Moderate risk

EPINEPHrine added to dextrose 5%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7018-1 D-0729-2023

Apr 28, 2023 Class II · Moderate risk

potassium phosphate 30 mmole added to 0.9% sodium chloride 500 mL per bag

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7016-1 D-0728-2023

Apr 28, 2023 Class II · Moderate risk

PHENYLephrine added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7011-1 D-0727-2023

Apr 28, 2023 Class II · Moderate risk

heparin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-7009-1 D-0726-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6176-1 D-0725-2023

Apr 28, 2023 Class II · Moderate risk

PHENYLephrine added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6092-1 D-0724-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6078-1 D-0723-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6076-1 D-0722-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to dextrose 5%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6075-1 D-0721-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6074-1 D-0720-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to dextrose 5%

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6073-1 D-0719-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6071-1 D-0718-2023

Apr 28, 2023 Class II · Moderate risk

vancomycin added to 0.9% sodium chloride

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6064-1 D-0717-2023

Apr 28, 2023 Class II · Moderate risk

potassium phosphate 15 mmole added to 0.9% sodium chloride 250 mL per bag

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. NDC 71285-6060-1 D-0716-2023

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061